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Abstract
Abnormal vaginal discharge in a pregnant woman causes discomfort and increas‐
es risk of complications. Management of such patient is difficult as the physician
will need to distinguish leucorrhoea of pregnancy from pathological vaginal dis‐
charge and also to decide on the drugs to prescribe that are not contraindicated in
pregnancy.
The objective of the study is to discuss the prevalence, causes and treatment of ab‐
normal vaginal discharge in pregnant women.
Searches from PubMed and using other scientific search engines were performed.
The chapter was supported with findings from the authors’ previous study on the
same topic. In the study, high vaginal and endocervical swab samples were collect‐
ed from 400 pregnant women with complaints of abnormal vaginal discharge and
another 400 controls.
The result showed that the prevalence of abnormal vaginal discharge in pregnan‐
cy was 31.5%. Vulval pruritus, 200 (75%), was a significant feature (χ2 = 1.011, P <
0.001), and Candida albicans, 160 (40%), was the commonest cause.
Although antibiotic sensitivity testing was not done for Candida albicans, all the mi‐
croorganisms were sensitive to Augmentin®
The prevalence of abnormal vaginal discharge in pregnancy was high and C. albi‐
cans  was the commonest  cause.  Assessment of  pregnant woman complaining of
vaginal discharge for aetiology is necessary in order to give an appropriate treat‐
ment.
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1. Introduction
Most pregnant women have vaginal discharges that are either physiologic or pathologic. The
challenge to the clinician is to separate the vaginal infections with potentially serious input for
pregnancy from annoying but not serious secretions, irritation and pruritus [1]. Infectious
vaginitis is usually caused by yeast, such as Trichomonas vaginalis, bacterial vaginosis, gonor‐
rhoea, Chlamydia trachomatis, Mycoplasma, Group B streptococcus or herpes [1]. Normal vaginal
secretions consist of water, electrolytes, epithelial cells, microbial organisms, fatty acid and
carbohydrate compounds [1, 2].The concentration of anaerobic bacteria is usually five times
than that of aerobic organisms. The most prevalent organisms in the vagina are lactobacilli,
Streptococci, Staphylococcus epidermidis, Gadnerella vaginalis and Escherichia coli. Anaerobic
species that are frequently isolated include Peptostreptococci, anaerobic lactobacilli and bacter‐
oides [3].
Vaginal pH, glycogen content and amount of secretion influence the quantity and type of
organisms present  in  the  vagina.  Lactobacilli  restrict  the  growth  of  other  organisms by
producing lactic acid, thus maintaining a low pH. These organisms also produce hydrogen
peroxide, which is toxic to anaerobes. The normal vaginal bacterial population assists in
inhibiting the growth of pathologic vaginal organisms. If the normal vaginal ecosystem is
altered, there is a greater chance of proliferation of pathogenic organisms. The challenge of
treating vaginitis in pregnancy is the necessity of making accurate diagnosis and treating
correctly [2]. True infections (some of which can have dangerous effect on gestation) must
be separated and distinguished from the exaggeration of physiologic discharge by pregnan‐
cy. Infection with bacterial vaginosis, Chlamydia trichomonas or Group B Streptococcus has
been  associated  with  septic  abortion,  premature  rupture  of  membranes  and  premature
delivery [2, 4].
2. Management of common causes of abnormal vaginal discharge in
pregnancy
2.1. Vulvovaginal candidiasis
Vulvovaginal candidiasis (VVC) is a common cause of vaginal discharge worldwide [5, 6]. It
is estimated that approximately 75% of women will experience an episode of VVC [7].
Candidiasis is caused by the fungus, Candida species. Candida species include Candida albi‐
cans, Candida tropicalis, Candida pseudotropicalis, Candida krusei and Candida stellaloidea. Other
strains are torulopsis, glabrata and rhodotromla. C. albicans accounts for 60–80% of vaginal fungal
infection [5–7], Candida glabrata accounts for 20% and C. tropicalis accounts for 6–23% [5].
Predisposing factors to VVC include pregnancy, diabetes mellitus, immunosuppressive
therapy (cytotoxic drugs, steroids, etc.), antibiotics, oral contraceptives, immunodeficient
conditions (HIV, cancer, chronic illness) and tight fitting and nylon undergarments [5]. Heat
and moisture favour the growth of Candida species [8]. VVC can be sexually transmitted, and
several studies reported an association between candidiasis and orogenital sex [7, 9].
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C. albicans can be identified by culture from the vagina during pregnancy in approximately
25% of women [10]. While the prevalence of VVC in pregnancy in Zabrze of Poland is 42% [11],
few studies in Africa reported the prevalence of 65% [12], 42% [13] and 23% [14] in Benin City
of Nigeria, Addis Ababa of Ethiopia and Papua of New Guinea, respectively. Similarly, studies
in India reported incidences ranging from 45% to 61% [15, 16].
Most patients with VVC will complain of vaginal discharge [5]. Dyspareunia, vulval pruritus
and burning are the main symptoms [17]. Patients commonly complain of pruritus and
burning after intercourse or upon urination. Erythema and oedema of the labia majora and
minora and rashes on the perineum and thighs may be seen on physical examination, and a
whitish, thick and curd-like vaginal discharge is usually present [17]. Recurrence requiring
repeated treatment during pregnancy is likely [18].
The diagnosis is made on both clinical examination and laboratory identification of Candida
by positive wet-mount test  or potassium hydroxide (KOH) preparation [17].  In the wet-
mount test, the spores and Candida are seen when vaginal discharge or scrapings from vulval
lesions are mixed with normal saline and viewed under high-power magnifications. The
presence of yeast blastospores or pseudohyphae can be detected in approximately 30–50%
of patients with symptomatic VVC [17]. The addition of 10% KOH to the solution lyses white
blood cells, red blood cells and vaginal epithelial cells, making the alkali-resistant branch‐
ing budding hyphae of Candida easier to see[17]. Because vaginal pH usually remains normal
in VVC, positive results from these two tests in combination with a normal vaginal pH are
helpful in confirming the diagnosis. Most studies demonstrate that most of vaginal isolates
are C. albicans [17]. Therefore, fungal cultures have not been used by most clinicians as part
of the initial evaluation [17].
Various drug formulations are effective in treating both uncomplicated and complicated
infections [10]. Both intravaginal and oral agents are available [10, 19]. Uncomplicated VVC
includes sporadic or infrequent VVC, mild-to-moderate VVC, VVC with likely infecting agent
being C. albicans, and non-immunocompromised patient. Complicated VVC is recurrent
candidal infection or severe infection or non-albicans candidiasis (C. tropicalis, C. glabrata, etc.),
VVC in uncontrolled diabetes mellitus, VVC with associated immunosuppression, VVC with
debilitation or VVC in pregnancy [10]. Women who have four or more candidal infections
during a year are classified as having complicated disease [9]. Intravaginal agents used in the
treatment of VVC are 5 g of 2% butoconazole cream intravaginally for 3 days or 5 g (sustained-
release) once; 5 g of 1% clotrimazole cream for 7–14 days or 100 mg tablet intravaginally for 7
days; 5 g of 2% miconazole cream intravaginally for 7 days or 100 mg suppository intravagi‐
nally for 7 days or 200 mg suppository for 3 days or 1200 mg suppository once; Nystatin 100,000
U tablet intravaginally for 14 days; 5 g of 6.5% tioconazole ointment intravaginally once; 5 g
of 0.4% terconazole cream intravaginally for 7 days or 0.8% cream 5 g intravaginally for 3 days
or 80 mg suppository intravaginally for 3 days. Oral agent is fluconazole 150 mg oral tablet
once.
Prolonged local intravaginal therapy regimens and addition of oral fluconazole may be
required to treat non-albicans VVC [7]. Fluconazole, 100–200 mg weekly for 6 months, is also
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the drug for prevention of recurrent VVC, whereas 600 mg boric acid gelatine capsule
intravaginally daily for 2 weeks is useful in the management of non-albicans recurrent VVC [7].
2.2. Anaerobic bacterial infection and bacterial vaginosis
Vaginal flora of a normal asymptomatic reproductive-aged woman includes multiple aerobic
or facultative species as well as obligate anaerobic species [9]. Of these, anaerobes are pre‐
dominant and outnumber aerobic species approximately 10–1 [20]. These anaerobes include
gram-negative organisms such as Prevotella, Bacteroides, Fusobacterium species, and Veillonella
species and gram-positive bacilli such as Propionibacterium species, Eubacterium species and
Bifidobacterium species [9, 20]. These anaerobic bacteria cause non-specific vaginitis [5].
Bacterial vaginosis is characterised by a shift from normal vaginal population of lactobacilli to
anaerobes such as G. vaginalis, Prevotella, Bacteroides and Mobiluncus species and other bacteria
such as Mycoplasma and Ureaplasma species [20]. It is one of the most frequent conditions
encountered in reproductive health clinics throughout the world [20]. The condition had been
previously called Haemophilus vaginalis vaginitis, non-specific vaginitis and G. vaginalis
vaginitis [5, 21].
Bacterial vaginosis has been strongly associated with poor pregnancy outcomes such as
preterm delivery and low birth weight infants, and several studies have now established the
associations between bacterial vaginosis, human immunodeficiency virus and puerperal
sepsis [20, 22].
Bacterial vaginosis appears to be particularly common in Sub-Saharan Africa where several
studies have reported high prevalence rates, ranging from 20–49% among women presenting
to STD clinics with vaginal discharge to 21–52% among pregnant women attending antenatal
clinic [20]. These are very much higher than the rates reported from industrialised countries
with 13% in the United Kingdom [23], 11% in London [20] and 15–30% in the United States [24].
Bacterial vaginosis usually occurs in sexually active patients. Some of the other risk factors
include multiple sexual partners, low socioeconomic status, lesbians, presence of intrauterine
device and prior STD [5]. It is still debatable whether it is sexually transmitted; however,
supporting this is the recovery of G. vaginalis in the urethral of male partners [5].
Bacterial vaginosis is characterised by a malodorous, profuse, thin, homogenous yellow, white
or grey discharge that is adherent to the anterior and lateral vaginal walls. Typically, the patient
may complain of a fishy odour during or shortly after coitus and also during menses. The
alkaline nature of blood or semen (pH > 7) brings about a transient increase in the vaginal pH,
and this causes the release of amines, which the patient perceives as fishy odour. This typical
discharge may be found on examination in some patients who in fact have not complained of
a vaginal discharge [25]. The fishy smell of the discharge is the main problem and is often
responsible for sexual disharmony between partners. Vulvitis and pruritus are very minimal
or totally absent. Nearly half of patients with BV have no symptoms. Obstetric complications
include premature rupture of foetal membranes, late miscarriage and postpartum endometri‐
tis, whereas pelvic inflammatory disease, post-hysterectomy cuff infection and postabortal
sepsis are some of the gynaecological complications [25].
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Diagnosis of BV can be based on the Amsel’s clinical criteria or the microbiological Nugent’s
scoring technique [26, 27]. In Amsel’s criteria, three of the following are required to diagnose
BV: (1) homogenous vaginal discharge; (2) vaginal pH greater than 4.5; (3) positive Whiff test
and (4) presence of clue cells on microscopy. The Nugent’s method relies on the identification
of categories of vaginal microflora based on quantitative assessment of a vaginal gram-stained
smear. The Nugent’s method has been extensively validated in industrialised countries where
assessment of vaginal microflora is an important step in understanding the pattern of flora
association with BV. Culture is the least accurate in making a diagnosis of BV as there is
overgrowth of many vaginal organisms in this condition [5]. Though virtually, all patients with
BV have G. vaginalis isolated on culture, it must also be noted that the organism can also be
cultured in 40–50% of women with normal flora [5].
In pregnancy, BV should be treated with metronidazole 250 mg three times a day (alterna‐
tives; metronidazole 2 g single dose, clindamycin 300 mg twice a day; or metronidazole gel)
[5]. The standard treatment of BV in non-pregnant women is oral metronidazole 500 mg twice
daily for 7 days; clindamycin cream 2% on applicator ful (5 g) intravaginally at bedtime for
7 days or metronidazole gel one applicator ful (5 g) intravaginally once or twice a day for 5
days [5, 10, 28].
2.3. Trichomoniasis
Trichomoniasis is the commonest sexually transmitted disease worldwide [5]. It was originally
thought to be innocuous but has now been found to be associated with preterm labour,
premature rupture of membranes, increased perinatal loss and pelvic inflammatory disease
(PID) [5, 29]. T. vaginalis can be identified during perinatal examination in as many as 20% of
women [29].
T. vaginitis is caused by the trichomonas organism, which is a small, flagellated, motile and
anaerobic protozoan. The particular trichomonad responsible for vaginitis is T. vaginalis, which
is the type found in the vagina. Other trichomonads, which include Trichomonas buccalis found
in the mouth and Trichomonas hominis found in the anal canal and rectum, are known but do
not cause vaginal discharge because they cannot survive in the vagina. T. vaginalis has been
demonstrated in the male urethra and prostate gland.
T. vaginalis is usually transmitted sexually. The organism may survive for several hours in
urine, wet towels and even on toilet seats. The possibility of transmission by these routes had
been suggested but not completely proven [5]. Incubation period is 4–20 days with an average
of 7 days. Males are usually asymptomatic, but they can easily infect treated female.
The prevalence of trichomoniasis in pregnancy has been found to be 7.5–19% [14, 30]. A
prevalence of 10.1% has been reported from the Gambia, West Africa [20].
The vaginal discharge of trichomoniasis is malodorous, frothy and profuse, thin creamy or
slightly greenish and may cause itching. The classic yellow–green discharge is found in 20–
50% of patients [5]; more often, the discharge is grey or white. The patient may also complain
of dyspareunia, postcoital bleeding, pruritus vulvae, frequency of micturition and dysuria.
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Characteristically, vulvitis is minimal or absent compared with candidiasis. On speculum
exam, apart from the discharge, a cervical erosion may be seen, and in severe cases, multiple,
small punctuate haemorrhages and swollen papillae may be found on the cervix (“straw berry”
cervix) and vagina [17].
The vaginal pH is usually 5–5.5 in trichomonas infection [17]. Applying litmus to the unlubri‐
cated speculum after it has been withdrawn from the vagina easily tests the pH. A saline wet
mount of the swab taken from the vagina or cervix will show motile flagellated protozoa and
leucocytes. Wet mount alone detects 64% infection in asymptomatic women, 75% of those with
clinical vaginitis and 80% of those with characteristic symptoms [5]. The use of culture
(Feinberg-Whittington or Diamond culture) gives a sensitivity of 86–97% [5]. Pap smear has a
detection rate of about 50–86% [5]. Monoclonal antibody staining is also used. It is sensitive
and is reported to detect 77% of those missed on wet mount [5].
Metronidazole is effective in eradicating T. vaginalis administered orally in a single 2 g dose
[5, 10]. Ootrimazole, which is both a fungicide and trichomonacide, can be used intravaginally
usually in pregnancy in the same dosage regime as in candidiasis [5]. In persistent infection,
it is best to treat the patient and her male sexual partner simultaneously.
2.4. Gonorrhoea and chlamydial infection
Chlamydia and gonorrhoea can both cause vaginal discharge in pregnancy and a major cause
of morbidity among women in developing countries [31]. Both infections have been associated
with pregnancy-related complications [32]. These two conditions are prevalent worldwide
particularly in Africa [20]. They are a major cause of acute pelvic inflammatory disease,
infertility and adverse pregnancy outcomes [20].
The prevalence of Chlamydia and gonorrhoea among pregnant women in Africa, in several
studies, is between 6–13% [4, 33] and 2–8% [4, 34], respectively. According to the WHO,
globally new cases of C. trachomatis infection have been estimated as 92 million, including 19
million in Sub-Saharan Africa [35–37]. In Maiduguri, North-eastern Nigeria, Amin et al.
reported a prevalence of 9% [38].
Chlamydia is characteristically asymptomatic [39, 40]. About one-third of patients may have
symptoms including mucopurulent vaginal discharge [5]. The role of Chlamydia in infertility
is well documented [39–42]. Tubal pathology in Chlamydia infection is the cause of infertility
in 10–30% of couples in developed countries and in up to 85% in developing countries [36, 37,
43, 44]. The main cause of tubal pathology is PID. Several different methods to diagnose
chlamydial infection are available. Great studies have been performed in the areas of reliable
methods of diagnosis [40, 45]. Chlamydia culture is considered as the gold standard because it
has near 100% specificity [40, 45]. Because only viable infectious chlamydial elementary bodies
are detected by culture, this is the method of choice for medico-legal issues. The disadvantages
of culture include its low sensitivity and is that it depends on the laboratory inter-personal
experience [46]. Non-culture methods include enzyme immunoassay (EIA), direct fluorescent
staining with monoclonal antibodies (DFA), nucleic acid amplification tests (NAATs) and
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nucleic acid hybridisation techniques. In the management of chlamydial infection, both the
patient and her infected sexual partner must be treated. It is, therefore, important to screen the
sexual partners and treat those who are infected. With the advent of single-dose therapy,
patients are now diagnosed and treated with the highest convenience and reliability [47].
Antimicrobial groups effective against C. trachomatis include the tetracyclines, macrolides,
quinolones and penicillins [47].
Most women with gonorrhoea are asymptomatic [48]. When symptoms occur, they are
localised to the lower genitourinary tract and include vaginal discharge, urinary frequency or
dysuria and rectal discomfort. The incubation period is only 3–5 days [48]. The vulva, vagina,
cervix and urethra may be inflamed and may itch or burn. Specimens of discharge from the
cervix, urethra and anus should be taken for culture from the symptomatic patients. A stain
of purulent urethra exudates may demonstrate gram-negative diplococci in leucocytes. Similar
findings in a purulent cervical discharge are less conclusively diagnostic of Neisseria gonor‐
rhoea. Gram-negative diplococci that are oxidase positive and obtained from selective media
(Thayer-Martin or Transgrow) usually signify N. gonorrhoea. Carbohydrate fermentation tests
may be performed, but in addition to being time consuming and expensive, they occasionally
yield other species of Neisseria. Therefore, cultures are reported as presumptive for N.
gonorrhoea. In addition, other techniques for detecting gonorrhoea include EIA for cervical
swab or urine specimens, DNA probes for endocervical swabs and NAATs for endocervical
swabs, liquid Papanicolaou specimens, vaginal swabs and urine specimens. Any patient with
gonorrhoea must be suspected of having other STDs and managed accordingly. Treatment
should cover N. gonorrhoea, C. trachomatis and incubating syphilis. Dual therapy has contrib‐
uted greatly to the declining prevalence of Chlamydia infection. Therefore, if chlamydial
infection is not ruled out, doxycycline (for non-pregnant women) should be added to ceftriax‐
one or azithromycin.
3. Outcome of study on abnormal vaginal discharge among pregnant
women conducted in Maiduguri, Borno State in North-eastern Nigeria
3.1. Goal and objectives
The general objective of the study is to detect the clinical features associated with abnormal
vaginal discharge and antibiotic sensitivity pattern of the causative microorganisms in
pregnant women to improve the early diagnosis and prompt treatment. The specific objectives
were as follows:
1. To determine the prevalence of abnormal vaginal discharge as a presenting complaint in
pregnancy
2. To determine the frequency of bacterial causes of abnormal vaginal discharge in preg‐
nancy and symptoms associated with it
3. To evaluate the sensitivity of microbial isolates from the vaginal discharge to antibiotics
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3.2. Methodology
Borno State lies between latitude 10° and 14° north and longitude 14° and 45° east. It is located
in the north-eastern part of Nigeria. Maiduguri is the capital city. The University of Maiduguri
Teaching Hospital (UMTH) is a tertiary health institution and is the only functional teaching
hospital in the north-eastern zone of Nigeria. The 2006 Nigerian provisional census puts the
population of Borno State at 4,151,193 with 1,990,036 females [49].
It was a cross-sectional analytical study. The study population consisted of pregnant women
presenting to the antenatal clinic with complaint of abnormal vaginal discharge while pregnant
women without complaints of abnormal vaginal discharge attending the antenatal clinic of the
hospital served as controls. A sample size of 800, consisting of 400 cases and 400 controls, was
obtained using Taylor’s and Kish’s formulas [50]. Information on sexual and reproductive risk
factors and symptoms was obtained. Vaginal examination was performed, and discharge was
assessed. Endocervical and high vaginal swabs were collected and immediately processed in
accordance with microbiological standard. Infection with Candida species was diagnosed by
microscopy of a saline mount, which showed a highly refractile, round or oval budding yeast
cells, and gram-stained smear of material from the vagina showed gram-positive pseudohy‐
phae with budding yeast cells; T. vaginalis was diagnosed by microscopy of a saline mount for
actively motile, spear-shaped flagellates, whereas bacterial vaginosis was diagnosed using
Amsel’s criteria [26]. N. gonorrhoea was identified by typical colonial morphology, reactions to
gram stain, positive oxidase test and sugar fermentation. The antibiotic sensitivity of isolates
was tested by the agar diffusion method on chocolate agar plates using oxoid multi discs with
standard antibiotic concentration.
The computer program SPSS V 20.0 (2010) Inc., Illinois, United States was used to analyse the
results; the association between organisms and studied variables was compared using chi-
square (χ2) and Fisher’s exact tests while P value <0.05 was considered significant at 95%
confidence level.
3.3. Results
During the period of study, 1280 pregnant women were seen at the antenatal booking clinic
among which 800 satisfied the inclusion criteria. Four hundred of the pregnant women
complained of abnormal vaginal discharge (cases), whereas 400 had no complaint of vaginal
discharge, giving a prevalence of abnormal vaginal discharge in pregnancy of 31.5%.
Table 1 shows the clinical features associated with vaginal discharge in the study group. Vulval
pruritus was present in 266 patients, and 200 (75%) of them complained of vaginal discharge,
whereas 66 (25%) were in the control group. There was a significant association between
pruritus and vaginal discharge (χ2 = 1.011, P < 0.001). As much as 63% of those without itching
were in the control group. Dysuria showed statistically significant association with vaginal
discharge (χ2 = 44.008, P < 0.000) with 74 (83%) of the 89 patients who complained of dysuria
having vaginal discharge. There was no statistically significant association between dyspar‐
eunia and vaginal discharge (χ2 = 2.082, P = 0.149). The only patient that had vulval wart
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complained of vaginal discharge, there was, however, no statistically significant association
between vulval warts and abnormal vaginal discharge.
Figure 1. (Findings from culture of ECS/HVS from pregnant women with abnormal vaginal discharge (N=400)) shows
outcome of culture and microscopy from vaginal discharge specimens collected from women with complaint of vagi‐
nal discharge. The prevalence of positive culture was 77% (308) among the cases and 21.3% (85) among the control
group. Of the 400 patients with abnormal vaginal discharge, the commonest microorganism found was C. albicans, 160
(40%), whereas N. gonorrhoea infection was the least, 1(0.2%). E. coli was isolated in 20 (5%), T. vaginalis in 7 (1.8%),
Staphylococcus aureus in 36 (9%), Klebsiella species in 8 (2%), G. vaginalis in 68 (17%) and Streptococcus species in 8 (2%) of
the pregnant women. Samples from 92 (23%) patients had negative culture.
Feature Case Control Total
1. Vulval itching Yes 200 (75 %) 66 (25 %) 266
No 200 (37 %) 334 (63 %) 534
x2 = 1.011, P < 0.001
2. Dysuria Yes 74 (83 %) 15 (17 %) 89
No 326 (46 %) 385 (54 %) 711
x2 = 44.008, P = 0.000
3. Dyspareunia Yes 25 (61 %) 16 (39 %) 41
No 375 (49 %) 384 (51 %) 759
x2 = 2.082, P = 0.149
4. LATa Yes 24 (60 %) 16 (40 %) 40
No 376(49 %) 384 (51 %) 760
x2 = 1.684, P = 0.194
5. Vulval warts Yes 1 (100 %) 0 (0 %) 1
No 399 (49.9 %) 400 (50.1 %) 799
x2 = 1.001, P = 0.317
aLower abdominal tenderness.
Table 1. Clinical features associated with vaginal discharge in the study group (N = 800).
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Table 2 shows the association between the bacterial isolates and their antibiotic sensitivity
patterns. G. vaginalis was sensitive to augmentin and ofloxacin in 64% of cases. Streptococ‐
cus sp. was most sensitive to augmentin and erythromycin in 92% (12/13) and 84% (11/13) of
cases, respectively. N. gonorrhoea was sensitive to augmentin and ofloxacin in 100% of cases
but was 100% resistant to other antibiotics. E. coli was sensitive to cefuroxime and gentami‐
cin in 62% and 65% of cases, respectively. Most of the microbial isolates were resistant to
ampicillin and norbactam. Only augmentin had greater than 60% sensitivity rate to all the
isolated microorganisms.
Antibiotics S. aureus Klebsiella sp. E. coli G. vaginalis Streptococcus sp. N. Gonorrhoea
Amoxicillin 16.9 10.5 14.2 35.9 0 0
Augmentina 86 61.5 75 64 92 100
Ofloxacin 75 55 12.5 64 25 100
Ciprofloxacin 64 51 25 9.2 22.5 0
Erythromycin 45 1.2 25 72 84 0
Cefuroxime 50 50 62 26 50 0
Gentamicin 61 64 65 21 30 0
Ampicillin 25 45.5 0 7.2 0 0
Norbactam 17.5 25 4.2 0 0 0
aAmoxicillin-clavulanic acid.
Table 2. Antibiotic sensitivity rate (%) of isolated bacteria.
4. Conclusion
Vaginal discharge in pregnancy is common, but distinguishing abnormal vaginal discharge
from normal leucorrhoea of pregnancy is challenging. Since findings have showed that the trio
of vaginal candidiasis, trichomoniasis and bacterial vaginosis are common causes of abnormal
vaginal discharge in pregnancy; efforts must be made to exclude these conditions in pregnant
patients presenting with vaginal discharge so that appropriate treatment can be instituted
timely. Finally, gonococcal infection must also be excluded since though it is less prevalent
than others, it is a major cause of morbidity in women in developing countries.
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